| Name | Title | Contact Details |
|---|
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.
Perhaps the most important decision in determining the destiny of Ferndale Laboratories, Inc. was made in the Fall of 1975. At that time, Ferndale Laboratories, Inc. embarked on a mission to grow from a local pharmaceutical manufacturer to a company with
Moderna COVID-19 Vaccine Clinic and Health Fair Let’s do our part! Corktown Health is offering the Moderna COVID-19 vaccine on 5/21, 5/28, 6/1, 6/4, and 6/5 from 8:30am to 1pm. We will also be offering vaccines at the Hazel Park Recreation Center on 6/...
Join us in the fight to end the mental health crisis plaguing our campuses and transform the future of mental health.